Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal Cancers. This milestone represents a significant step forward for OCB and the ToxNav ® brand. ToxNav ® is OCB’s flag…
Professors David and Rachel Kerr’s proposed colorectal cancer treatment guidelines for patients during the COVID-19 era. AIMS METHODS We have modified the guidelines in such a way that we believe will decrease the TOTAL number of patients receiving chemotherapy (particularly…
Press Release Oxford Cancer Biomarkers, Tuesday 6th November 2018. OCB is pleased to announce that it is an SME partner to University Hospital Coventry and Warwickshire NHS Trust’s successful bid for the PathLAKE project. Greg Clark, UK Secretary of State…